<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">Colorectal cancers</z:e> commonly carry truncation mutations in the <z:mpath ids='MPATH_271'>adenomatous polyposis coli</z:mpath> (APC) gene </plain></SENT>
<SENT sid="1" pm="."><plain>The APC protein contributes to the stabilization of microtubules </plain></SENT>
<SENT sid="2" pm="."><plain>Consistently, microtubules in cells lacking APC depolymerize more readily in response to microtubule-destabilizing drugs </plain></SENT>
<SENT sid="3" pm="."><plain>This raises the possibility that such agents are suitable for treatment of APC-deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, APC-deficient cells have a compromised spindle assembly checkpoint, which renders them less sensitive to killing by microtubule poisons whose toxicity relies on the induction of prolonged mitotic arrest </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we describe the novel discovery that the clinically used microtubule-depolymerizing drug <z:chebi fb="0" ids="480999">vinorelbine</z:chebi> (Navelbine) kills APC-deficient cells in culture and in intestinal tissue more effectively than it kills <z:mp ids='MP_0002169'>wild-type</z:mp> cells </plain></SENT>
<SENT sid="6" pm="."><plain>This is due to the ability of <z:chebi fb="0" ids="480999">vinorelbine</z:chebi> to kill cells in interphase independently of mitotic arrest </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with a role for p53 in cell <z:hpo ids='HP_0011420'>death</z:hpo> in interphase, <z:mpath ids='MPATH_63'>depletion</z:mpath> of p53 renders cells less sensitive to <z:chebi fb="0" ids="480999">vinorelbine</z:chebi>, but only in the presence of <z:mp ids='MP_0002169'>wild-type</z:mp> APC </plain></SENT>
<SENT sid="8" pm="."><plain>The pro-apoptotic protein BIM (also known as BCL2L11) is recruited to mitochondria in response to <z:chebi fb="0" ids="480999">vinorelbine</z:chebi>, where it can inhibit the anti-apoptotic protein BCL2, suggesting that BIM mediates <z:chebi fb="0" ids="480999">vinorelbine</z:chebi>-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>This recruitment of BIM is enhanced in cells lacking APC </plain></SENT>
<SENT sid="10" pm="."><plain>Consistently, BIM <z:mpath ids='MPATH_63'>depletion</z:mpath> dampens the selective effect of <z:chebi fb="0" ids="480999">vinorelbine</z:chebi> on these cells </plain></SENT>
<SENT sid="11" pm="."><plain>Our findings reveal that <z:chebi fb="0" ids="480999">vinorelbine</z:chebi> is a potential therapeutic agent for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but they also illustrate the importance of the APC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor status when predicting therapeutic efficacy </plain></SENT>
</text></document>